Delving into the Latest Updates on CSL Behring Lengnau AG with Synapse

概览

疾病领域	数量

血液及淋巴系统疾病	2

排名前五的药物类型	数量

重组凝血因子	2

排名前五的靶点	数量

F8(凝血因子VIII)	1
F10(凝血因子X)	1

关联

2

项与 CSL Behring Lengnau AG 相关的药物

Lonoctocog alfa

人凝血因子VIII

靶点

F8

作用机制

F8刺激剂

在研机构

CSL Behring LLC [+4]

原研机构

SK Chemicals Co. Ltd.

在研适应症

血友病A

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2016-05-25

Albutrepenonacog alfa

靶点

F10

作用机制

F10刺激剂 [+1]

在研机构

CSL Behring LLC [+3]

原研机构

CSL Behring LLC

在研适应症

血友病B [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

加拿大

首次获批日期2016-01-26

100 项与 CSL Behring Lengnau AG 相关的临床结果

登录后查看更多信息

0 项与 CSL Behring Lengnau AG 相关的专利（医药）

登录后查看更多信息

2

项与 CSL Behring Lengnau AG 相关的文献（医药）

2021-11-17·Synthetic Communications

Atom-economic thiophosphoroselenenylations of C–H acid esters and amides

作者: Przychodzeń, Witold ; Majewski, Arkadiusz

Three improved thiophosphoroselenenylation procedures of CH-acids, including derivatives of malonic and acetyl-, phosphono-, 4-nitrophenyl- and 3-pyridylacetic acids, have been described and compared to previously reported thiophosphoroselenylation of di-Et malonate using bis(disopropoxyphosphinothioyl)diselenide alone or with the aid of Me iodide.The use of iodine makes it possible to utilize both equivalent of the selenenylating agent.The procedures work well for the majority of nucleophiles in a pKa range between more acidic malononitrile or Meldrum acid and less acidic phenylacetates.The reaction carried out on di-Et malonate in boiling rectified ethanol yields selenoacetate, which cannot be obtained by direct phosphoroselenenylation.Crystal structure of one of the selenomalonamides confirms the stabilization effects of both carbonyl oxygens on selenium atom.The P-Se bond splitting, using TBAF in 3-M excess in the presence of alkylating agent yields the resp. C,Se-dialkyl derivatives

2020-05-12·Blood Advances2区 · 医学

FVIII half-life extension by coadministration of a D′D3 albumin fusion protein in mice, rabbits, rats, and monkeys

2区 · 医学

Article

作者: Beltz, Hans-Wilhelm ; Raquet, Elmar ; Lind, Holger ; Dower, Steven K. ; Weimer, Thomas ; Schulte, Stefan ; Simmonds, Jason ; Claar, Philipp ; Mischnik, Marcel ; Schmidt, Peter M. ; Andrews, Arna ; Tomasetig, Vesna ; Pestel, Sabine ; Tjärnlund-Wolf, Anna

AbstractA novel mechanism for extending the circulatory half-life of coagulation factor VIII (FVIII) has been established and evaluated preclinically. The FVIII binding domain of von Willebrand factor (D′D3) fused to human albumin (rD′D3-FP) dose dependently improved pharmacokinetics parameters of coadministered FVIII in all animal species tested, from mouse to cynomolgus monkey, after IV injection. At higher doses, the half-life of recombinant FVIII (rVIII-SingleChain) was calculated to be increased 2.6-fold to fivefold compared with rVIII-SingleChain administered alone in rats, rabbits, and cynomolgus monkeys, and it was increased 3.1-fold to 9.1-fold in mice. Sustained pharmacodynamics effects were observed (ie, activated partial thromboplastin time and thrombin generation measured ex vivo). No increased risk of thrombosis was observed with coadministration of rVIII-SingleChain and rD′D3-FP compared with rVIII-SingleChain alone. At concentrations beyond the anticipated therapeutic range, rD′D3-FP reduced the hemostatic efficacy of coadministered rVIII-SingleChain. This finding might be due to scavenging of activated FVIII by the excessive amount of rD′D3-FP which, in turn, might result in a reduced probability of the formation of the tenase complex. This observation underlines the importance of a fine-tuned balance between FVIII and its binding partner, von Willebrand factor, for hemostasis in general.

100 项与 CSL Behring Lengnau AG 相关的药物交易

登录后查看更多信息

100 项与 CSL Behring Lengnau AG 相关的转化医学

登录后查看更多信息